Insider Selling: Liquidia (NASDAQ:LQDA) General Counsel Sells $389,948.16 in Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 13,692 shares of the stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $389,948.16. Following the completion of the transaction, the general counsel directly owned 602,841 shares of the company’s stock, valued at approximately $17,168,911.68. This trade represents a 2.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Price Performance

LQDA stock opened at $34.78 on Friday. Liquidia Corporation has a 12-month low of $21.94 and a 12-month high of $93.61. The company has a market cap of $3.11 billion, a price-to-earnings ratio of 24.77 and a beta of 0.61. The firm has a 50 day moving average of $61.21 and a 200-day moving average of $61.73. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.49) earnings per share. As a group, equities analysts expect that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently bought and sold shares of LQDA. Globeflex Capital L P purchased a new stake in shares of Liquidia in the second quarter valued at $175,000. Nykredit A S acquired a new stake in shares of Liquidia during the second quarter valued at $177,000. Hurley Capital LLC increased its position in Liquidia by 140.7% during the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock worth $179,000 after purchasing an additional 3,040 shares in the last quarter. Apollon Wealth Management LLC purchased a new stake in Liquidia during the 1st quarter worth about $247,000. Finally, Archer Investment Corp purchased a new stake in Liquidia during the 1st quarter worth about $259,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wedbush set a $58.00 price objective on shares of Liquidia in a research report on Friday, October 2nd. Piper Sandler set a $129.00 target price on shares of Liquidia in a report on Friday, July 24th. Raymond James Financial restated an “outperform” rating on shares of Liquidia in a report on Thursday, October 8th. Jefferies Financial Group upgraded shares of Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. Finally, Bank of America upped their price target on shares of Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $72.85.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).